MF59-Adjuvanted seasonal influenza vaccine including H1N1 leads to robust serological response rates in immunocompromised patients after liver and kidney transplantation

Abstract

Background and aims: Influenza infection in solid-organ transplant recipients leads to increased morbidity and mortality. Vaccination is preventive despite lower efficacy with approved non-adjuvanted vaccines. The aim of this study was to evaluate the immunogenicity and safety of the MF59-adjuvanted influenza vaccine 2010/11 (Fluad®) in liver/kidney transplant recipients under immunosuppression compared to healthy subjects.